Compensation of the Board of Directors for 2024
The following table discloses the compensation paid to the members of the Board of Directors for financial year 2024 while performing services for medmix:
|
|
|
2024 |
||||||
|
thousands of CHF |
|
Cash fees |
|
Restricted share unit (RSU) plan 3) |
|
Social security contributions 4) |
|
Total |
|
Rob ten Hoedt, Chairman |
|
150 |
|
150 |
|
22 |
|
322 |
|
Barbara Angehrn |
|
65 |
|
65 |
|
10 |
|
140 |
|
Daniel O. Flammer |
|
65 |
|
65 |
|
10 |
|
140 |
|
David Metzger |
|
65 |
|
65 |
|
10 |
|
140 |
|
Marco Musetti |
|
73 |
|
73 |
|
12 |
|
158 |
|
René Willi 1) |
|
26 |
|
6 |
|
3 |
|
35 |
|
Susanne Hundsbaek-Pedersen 2) |
|
45 |
|
65 |
|
9 |
|
119 |
|
Board of Directors |
|
489 |
|
489 |
|
77 |
|
1’055 |
1) Member of the Board of Directors until May 31, 2024.
2) Member of the Board of Directors from April 24, 2024.
3) RSU awards granted in 2024. Grant price was CHF 15.69 (three-month volume weighted average share price) and fair value was CHF 15.02.
4) The amount includes mandatory social security contributions on the cash fees and estimated contributions on the RSU (based on their fair value at grant) paid by the company on behalf of the Board members.
The following table discloses the compensation paid to the members of the Board of Directors for financial year 2023 while performing services for medmix:
|
|
|
2023 |
||||||
|
thousands of CHF |
|
Cash fees |
|
Restricted share unit (RSU) plan 3) |
|
Social security contributions 4) |
|
Total |
|
Rob ten Hoedt, Chairman |
|
131 |
|
150 |
|
21 |
|
302 |
|
Barbara Angehrn |
|
70 |
|
65 |
|
11 |
|
146 |
|
Daniel O. Flammer |
|
70 |
|
65 |
|
11 |
|
146 |
|
David Metzger |
|
68 |
|
65 |
|
11 |
|
144 |
|
Greg Poux-Guillaume 1) |
|
95 |
|
60 |
|
12 |
|
167 |
|
Marco Musetti |
|
78 |
|
73 |
|
12 |
|
163 |
|
René Willi 2) |
|
70 |
|
65 |
|
11 |
|
146 |
|
Board of Directors |
|
582 |
|
543 |
|
89 |
|
1’214 |
1) Member of the Board of Directors from September 20, 2021 to April 24, 2024.
2) Member of the Board of Directors until May 31, 2024.
3) RSU awards granted in 2023. Grant price was CHF 21.57 (three-month volume weighted average share price) and fair value was CHF 20.65.
4) The amount includes mandatory social security contributions on the cash fees and estimated contributions on the RSU (based on their fair value at grant) paid by the company on behalf of the Board members.
As of December 31, 2024 and 2023, respectively, there were no outstanding loans or credits granted to the members of the Board of Directors, former members of the Board of Directors or related parties. In 2024 and 2023, respectively, no compensation was granted to former members of the Board of Directors or related parties.
Reconciliation between the reported board compensation and the amount approved by the shareholders at AGM
At the AGM 2024, shareholders approved a maximum aggregate compensation amount of CHF 1'500'000 for the Board of Directors for the period of office from the 2024 AGM until the end of the 2025 AGM. The table below shows the reconciliation between the compensation that was/will be paid out for the periods of office and the maximum aggregate compensation amounts approved by the shareholders.
|
thousands of CHF |
|
Compensation earned during financial year as reported (A) |
|
Less compensation earned from Jan to AGM of financial year (B) |
|
Plus compensation accrued from Jan to AGM of year following financial year (C) |
|
Total compensation earned for the period from AGM to AGM of medmix (A-B+C) |
|
Amount approved by shareholders at respective AGM |
|
Ratio between compensation earned for the period from AGM to AGM versus amount approved by shareholders |
|
2024 AGM - 2025 AGM |
|
2024 |
|
January 01, 2024 to 2024 AGM medmix |
|
January 01, 2025 to 2025 AGM medmix |
|
2024 AGM to 2025 AGM |
|
2024 AGM |
|
2024 AGM |
|
Board of Directors Total 1) |
|
1’055 |
|
169 |
|
149 |
|
1’035 |
|
1’500 |
|
69.0% |
|
|
|
Compensation earned during financial year as reported (A) |
|
Less compensation earned from Jan to AGM of financial year (B) |
|
Plus compensation accrued from Jan to AGM of year following financial year (C) |
|
Total compensation earned for the period from AGM to AGM of medmix (A-B+C) |
|
Amount approved by shareholders at respective AGM |
|
Ratio between compensation earned for the period from AGM to AGM versus amount approved by shareholders |
|
2023 AGM - 2024 AGM |
|
2023 |
|
January 01, 2023 to 2023 AGM medmix |
|
January 01, 2024 to 2024 AGM medmix |
|
2023 AGM to 2024 AGM |
|
2023 AGM |
|
2023 AGM |
|
Board of Directors Total |
|
1’214 |
|
202 |
|
197 |
|
1’208 |
|
1’500 |
|
80.6% |
1) Expense allowance not included, sice it is approved by the competent cantonal tax authority and does not qualify as compensation within the meaning of the compensation rules set forth the Swiss Code of Obligations.